Inify Laboratories has completed its new laboratory – including staffing up with skilled professionals – in less than a year.
“The laboratory has been finished in record time. We now have an ultramodern AI-based laboratory, and a dedicated team with a broad spectrum of expertise within digital pathology,” says CEO Fredrik Palm at Inify Laboratories.
Total costs so far are in line with our expectations, due to project planning and teamwork within the company’s interdisciplinary teams, as well as close collaboration with external suppliers.
“The fourth quarter sees us reaching practically all the milestones required to be able to start the new year with tests and validation of our complete system before we launch our diagnostic service for prostate cancer. The launch is expected to take place in the first half of 2023,” says Palm.
In early October, the company carried out successful tests of its unique IT system, where every part of the process is standardised with full traceability. The feedback from future customers – urology clinics and pathologists, with whom Inify has had a close dialogue – has been highly positive.
“The response exceeded our already high expectations, and we close the year with strong confidence that our first patients will be diagnosed according to schedule,” says Palm. “We continue at full speed towards our goal – setting a new world standard in pathological cancer diagnostics, for the benefit of doctors and patients.”
